12. Fasting blood glucose <200 mg/dL for treatment naïve T2DM subjects and <180 mg/dL for T2DM subjects on antidiabetic therapy at the Screening Visit (1 retest allowed after 24 hours; <220 mg/dL on all T2DM subjects on admission to the investigational site on Day -2).